Herantis Pharma Plc's half year financial report January 1 - June 30, 2018 (unaudited)
Herantis Pharma PlcCompany release August 29, 2018 at 9:00amDrug development progresses in randomized trialsHerantis Pharma Plc's half year financial report January 1 - June 30, 2018 (unaudited) Highlights in January-June 2018 (compared with January-June 2017): · Herantis Pharma's ("Herantis") investigational drug CDNF's clinical Phase 1-2 study for the treatment of Parkinson's disease expanded with two additional sites at the university hospitals in Helsinki and Lund in addition to the first site in Stockholm based on a favorable safety evaluation by the independent data